Matthew T. David

Matthew T. David is a declared insider at 2 companies (chief executive); the most frequent names are CorMedix Inc. and Actinium Pharmaceuticals, Inc. Between 3 September 2020 and 14 October 2026, the trades on record add up to 8 filings.

Purchases make up the whole of the open-market record (4 purchases, €16k). Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 4 share grants.

Half of the purchases are above €3,981 and half below. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 16 October 2026: a share grant, in Actinium Pharmaceuticals, Inc. The most recent open-market purchase was published on 7 December 2021, 1,779 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.